Sintx Technologies, Inc. (SINT)
| Market Cap | 8.29M |
| Revenue (ttm) | 1.03M |
| Net Income (ttm) | -17.61M |
| Shares Out | 4.32M |
| EPS (ttm) | -5.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,835 |
| Open | 1.810 |
| Previous Close | 1.860 |
| Day's Range | 1.810 - 1.965 |
| 52-Week Range | 1.810 - 6.780 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 9.13 (+375.52%) |
| Earnings Date | Aug 13, 2026 |
About SINT
Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. The company offers monolithic solid silicon nitride; solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyether ether ketone, and Polyether Ether Ketone (PEE). The company was formerly known as Amedica Cor... [Read more]
Financial Performance
In 2025, Sintx Technologies's revenue was $1.02 million, a decrease of -64.74% compared to the previous year's $2.89 million. Losses were -$17.08 million, 55.0% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for SINT stock is "Strong Buy." The 12-month stock price target is $9.13, which is an increase of 375.52% from the latest price.
News
Sintx Technologies Registration statement: Registration filing
Sintx Technologies filed a registration statement on June 25, 2026, providing details about a securities offering with the SEC.
Sintx Technologies files to sell 5.82M shares of common stock for holders
06:03 EDT Sintx Technologies (SINT) files to sell 5.82M shares of common stock for holders
Sintx Technologies receives $3.2M in purchase orders
Sintx Technologies (SINT) announced that it has received purchase orders from multiple contract manufacturing customers with an aggregate value exceeding $3.2M for the production of advanced ceramic c...
SINTX Technologies Announces Receipt of More Than $3.2 Million in Contract Manufacturing Purchase Orders
SALT LAKE CITY, Utah, June 22, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride ceramics and advanced material technolo...
Sintx Technologies Transcript: Transcript
Silicon nitride implants offer superior infection resistance and bone integration, targeting the fast-growing extremities market with FDA-cleared foot and ankle products. Strong surgeon adoption, robust IP, and strategic partnerships support a path to profitability within three years.
Sintx Technologies resumed with a Buy at Maxim
Maxim analyst Anthony Vendetti resumed coverage of Sintx Technologies (SINT) with a Buy rating and $6 price target
SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SALT LAKE CITY, Utah, June 03, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced biomaterials company focused on developing silicon nitride techn...
SINTX Technologies to Present at the LD Micro Invitational XVI Conference
Salt Lake City, Utah--(Newsfile Corp. - May 17, 2026) - SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), a medical technology company focused on advanced ceramics and silicon nitrid...
Sintx Technologies initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Sintx Technologies (SINT) with a Buy rating and $10 price target Sintx is developing silicon nitride-based biomaterials, which offer a “differentiated combination...
SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution
Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026
Sintx Technologies announces first in-human surgery using FDA-cleared Sinaptic
The company states: “SINTX Technologies (SINT) announced the successful completion of the first-in-human surgical procedure utilizing its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System, mark...
SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant
Major clinical milestone marks SINTX's entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platform
Sintx Technologies appoints Elmore as President
Sintx Technologies (SINT) announced the appointment of Ryan Elmore as President of SINTX Technologies, effective March 16, 2026. Elmore most recently served as Core Business Director at Invibio, a div...
SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms
Appointment supports acceleration of revenue opportunities from SiNERGY ™ silicon nitride devices and antipathogenic fibrous material technologies
SINTX Technologies to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4–5
SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride-bas...
Sintx Technologies signs supply agreement with EVONIK
SINTX Technologies (SINT) signed a supply agreement with Evonik to manufacture the Company’s proprietary silicon nitride-PEEK compound engineered for AI-assisted additive manufacturing of patient-spec...
SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants
Milestone enables immediate production of SiN/PEEK custom devices SALT LAKE CITY, Utah, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advance...
Sintx Technologies reports Q3 EPS ($3.46) vs ($6.96) last year
Reports Q3 revenue $208k vs $799k last year. “We have aligned SINTX squarely behind near-term commercial milestones with our advanced biomaterial products,” said Eric Olson, President and CEO of SINTX...
Sintx Technologies Earnings release: Q3 2025
Sintx Technologies released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
Sintx Technologies announces launch of OsseoSculpt
SINTX Technologies (SINT) announced the execution of a private label agreement to supply OsseoSculpt, a next-generation biologic designed to complement the Company’s FDA 510(K) cleared SINAPTIC Foot &...
SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biologic for Use with SINAPTIC® Foot & Ankle Osteotomy Wedge System
Clinical evaluation of the product by design surgeons completed, driving early commercial momentum SALT LAKE CITY, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SIN...
Sintx Technologies files to sell 1.74M shares of common stock for holders
The company is not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale by the selling stockholders of the shares. Published…
Sintx receives FDA clearance for SINAPTIC Foot, Ankle implant system
SINTX Technologies (SINT) announced U.S. Food and Drug Administration, FDA, 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System, enabling SINTX’s commercial entry into reconstructive...
SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System
FDA cleared and U.S. manufactured implant system positions SINTX to enter billion-dollar U.S. market SALT LAKE CITY, Utah, Oct. 20, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“S...
Sintx Technologies announces U.S. patent notice of allowance
SINTX Technologies (SINT) announced that the United States Patent and Trademark Office issued a Notice of Allowance for a patent application containing method claims covering the Company’s antipathoge...